2 ML rimabotulinumtoxinB 5000 UNT/ML Injection [Myobloc]
Semantic Scholar uses AI to extract papers important to this topic.
AbstractA systematic pair-wise comparison of all available botulinum toxin serotype A and B treatments for cervical dystonia (CD… Expand The global botulinum toxin (BT) market is currently undergoing rapid changes: this may be the time to review the history and the… Expand ObjectiveTherapeutic botulinum toxins are antigenic proteins with the potential to produce antibodies (Abs). It is, however… Expand Modern clinical use of botulinum toxin (BoNT) by doctors requires evidence-based facts and data to support their work. In… Expand Patient satisfaction with botulinum toxin treatment is a key success factor in aesthetic procedures and is governed by the… Expand Background: Botulinum toxin type B (BoNT/B) reduces saliva production, suggesting it may be useful for the treatment of… Expand Botulinum toxin is a neurotoxin produced by the Gram-positive, rod-shaped anaerobic bacterium Clostridium botulinum (1). First… Expand Injections of botulinum toxin have revolutionised the treatment of focal spasticity. Before their advent, the medical treatment… Expand Botulinum toxin type B (BoNT-B; Myobloc™) is a new botulinum toxin with demonstrated efficacy in patients with cervical dystonia… Expand Neck pain occurs in a majority of patients with cervical dystonia. The cause of pain is unknown but may be attributable to the… Expand